Found 446 results in Expert Content

The pharmaceutical industry has experienced a trend in the number of accelerated approval designations for drugs (e.g. orphan drugs, breakthrough therapies, accelerated approvals, and FDA priority reviews) being developed.

Incorporation of patient-focused drug design principles is increasingly becoming essential to ensure that a new drug is commercially successful and delivers the best patient outcomes.

Pharmaceutical and biotechnology companies value streamlined services from early-phase development to clinical supply services to commercialization.

Lipid formulation and spray-dried dispersions are widely used, and proven technologies to overcome bioavailability challenges for poorly soluble molecules.

We will review the current OTC remedies for cough, cold and allergy categories and discuss strategies to grow your share on shelf space with innovative dosage forms.

Watch this webinar to learn the key considerations for evaluating available technologies to find the most suitable bioavailability solution.

Read this article published by Pharmaceutical technology to learn about proven strategies for a successful product launch, including cross-functional team collaboration, risk management and using the right project management tools.

Read the latest article published by Pharmaceutical Technology giving an overview of elemental impurities testing and elemental impurities risk assessment process.

Understand why new therapies fail or succeed in the market place and learn when and how to apply advanced technologies to help increase the chance of success

Elemental impurities can arise from a variety of sources, such as active pharmaceutical ingredients (API), excipients, manufacturing equipment, and primary container closure systems.